
ANTX
Healthcare · Biotechnology · $172.6M market cap
$4.55+0.11 (+2.5%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +21.6% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | Before the open | -0.20 | -0.17 | +15.0% |
| Aug 11, 2026 | After the close | -0.24 | -0.18 | +25.0% |
| May 11, 2026 | After the close | -0.23 | -0.29 | -26.1% |
| Mar 18, 2026 | Time not confirmed | -0.24 | -0.29 | -20.8% |
| Nov 12, 2025 | After the close | -0.22 | -0.31 | -40.9% |
| Aug 14, 2025 | After the close | -0.31 | -0.21 | +32.3% |
| May 13, 2025 | After the close | -0.27 | -0.35 | -29.6% |
| Mar 25, 2025 | Time not confirmed | -0.27 | -0.25 | +7.4% |
| Nov 13, 2024 | After the close | -0.39 | -0.35 | +10.3% |
| Aug 13, 2024 | After the close | -0.59 | -0.48 | +18.6% |
| May 14, 2024 | After the close | -0.62 | -0.56 | +9.7% |
| Mar 28, 2024 | After the close | -0.75 | -0.57 | +24.0% |
| Nov 9, 2023 | After the close | -0.63 |
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an…
| -0.65 |
| -3.2% |
| Aug 10, 2023 | After the close | -0.85 | -0.81 | +4.7% |
| May 11, 2023 | After the close | -0.68 | -0.79 | -16.2% |
| Mar 29, 2023 | After the close | -0.65 | -0.61 | +6.2% |
| Nov 9, 2022 | After the close | -0.60 | -0.59 | +1.7% |
| Aug 11, 2022 | After the close | -0.47 | -0.53 | -12.8% |
| May 10, 2022 | After the close | -0.51 | -2.98 | -484.3% |
| Mar 28, 2022 | After the close | 0.00 | 0.00 | — |